ADMA Biologics: Wall Street Projects Robust Revenue Growth

ADMA Biologics (ADMA) has two commercialized assets in its portfolio, Nabi-HB and BIVIGAM, which it added through the acquisition of assets from Biotest Pharmaceuticals Corporation.

In fiscal 2018, ADMA Biologics reported revenues of $16.99 million, which marks a year-over-year decline of 25.37%. Wall Street analysts expect the company’s revenues to rise 33.50% year-over-year to $22.67 million in fiscal 2019, 164.26% to $59.92 million in fiscal 2020, and 76.19% to $105.57 million in fiscal 2021.

In the fourth quarter of 2018, ADMA Biologics reported revenues of $4.06 million, a year-over-year decline of 66.20%. Analysts expect the company’s revenues to fall 21.07% year-over-year to $3.19 million in the first quarter, fall 19.22% to $3.76 million in the second quarter, rise 57.72% $6.42 million in the third quarter, and rise 129.62% to $9.31 million in the fourth quarter of fiscal 2019.

WAKE UP WITH BAGELS AND STOCKS, OUR NEW EMAIL THAT ENTERTAINS AND INFORMS YOU BEFORE THE DAY STARTS. SIGN UP HERE!

In fiscal 2018, ADMA Biologics reported a net loss of $65.7 million, marking year-over-year deterioration of $22.0 million.

In fiscal 2018, ADMA Biologics reported non-GAAP EPS of -$1.45, a year-over-year increase of 12.12%. Wall Street analysts expect the company’s non-GAAP EPS to rise year-over-year 31.15% to -$1.00 in fiscal 2019, 51.59% to -$0.48 in fiscal 2020, and 74.14% to -$0.13 in fiscal 2021.

In the fourth quarter of 2018, ADMA Biologics reported non-GAAP EPS of -$0.39, a year-over-year decline of 34.48%. Analysts expect the company’s non-GAAP EPS to rise 26.67% to -$0.29 in the first quarter, 19.41% to -$0.27 in the second quarter, 24.85% to -$0.25 in the third quarter, and 45.64% to -$0.21 million in the fourth quarter of fiscal 2019.

According to the company’s 2019 10K filing, BPC, AmerisourceBergen, and McKesson Corporation are its major customers. These customers together accounted for 87% of ADMA’s total fiscal 2018 revenues.